NCT05195450View on ClinicalTrials.gov

TAF (Tenofovir Alafenamide) for Preventing Progression of Liver Disease in Non-cirrhotic Chronic HBV Infection With Normal ALT and Low Viral Load.

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Non-cirrhotic, Chronic Hepatitis B
Interventions
DRUG

Tenofovir alafenamide fumarate

• TAF 25 mg OD vs no treatment x 5 years and beyond

Trial Locations (1)

110070

RECRUITING

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER